{"entity":{"id":"nct06281964","kind":"trial","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","aka":["KANNON-2"],"tldr":"A phase 3 trial of pemetrexed in lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.","summary":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. is a phase 3, randomised interventional study registered as NCT06281964 by Avistone Biotechnology Co., Ltd., with a registry enrolment figure of 327 participants, started 2023-12-01 and due to reach its primary completion in 2028-06-30. Interventions recorded: PLB1004; Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Progression-Free Survival (PFS) by BICR. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\\~IV)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06281964","url":"https://clinicaltrials.gov/study/NCT06281964"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["pemetrexed"],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06281964","phase":"3","setting":"Randomized, Controlled, Open Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of PLB1004 Versus Platinum-based Chemotherapy With or Without Sintilimab of Advanced NSCLC With EGFR Exon 20 Ins Mutations","sponsor":"Avistone Biotechnology Co., Ltd.","enrolled":327,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06281964/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}